Novel insights into the neuroendocrinology of critical illness

European Journal of Endocrinology

Volumn 143, Issue 1, 2000, Pages 1-13

  Van Den Berghe, Greet ^a  

^a UNIVERSITY HOSPITALS LEUVEN   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

CORTICOTROPIN; GROWTH HORMONE; GROWTH HORMONE RELEASING FACTOR; LIOTHYRONINE; LUTEINIZING HORMONE; PROLACTIN; PROTIRELIN; SOMATOMEDIN C; THYROTROPIN;

CRITICAL ILLNESS; HORMONE RELEASE; HYPOTHALAMUS HYPOPHYSIS SYSTEM; NEUROENDOCRINOLOGY; PATHOPHYSIOLOGY; PRIORITY JOURNAL; REVIEW; STRESS; WASTING SYNDROME;

EID: 0033939971     PISSN: 08044643     EISSN: None     Source Type: Journal    
DOI: 10.1530/eje.0.1430001     Document Type: Review

References (98)

1. Streat SJ, Beddoe AH & Hill GL. Aggressive nutritional support does not prevent protein loss despite fat gain in septic intensive care patients. Journal of Trauma 1987 27 262-266.
2. Carroll P. Protein metabolism and the use of growth hormone and insulin-like growth factor-I in the critically ill patient. Growth Hormone and IGF Research 1999 9 400-413.
3. Van den Berghe G, Baxter RC, Weckers F, Wouters P, Bowers CY & Veldhuis JD. A paradoxical gender dissociation within the growth hormone/insulin-like growth factor I axis during protracted critical illness. Journal of Clinical Endocrinology and Metabolism 2000 85 183-192.
4. Knaus WA, Draper EA, Wagner DP & Zimmerman JE. APACHE II: a severity of disease classification system. Critical Care Medicine 1985 13 818-829.
5. Van den Berghe G, de Zegher F & Bouillon R. Acute and prolonged critical illness as different neuroendocrine paradigms. Journal of Clinical Endocrinology and Metabolism 1998 83 1827-1834.
6. Van den Berghe G, Wouters P, Weekers F, Mohan S, Baxter RC, Veldhuis JD et al. Reactivation of pituitary hormone release and metabolic improvement by infusion of growth hormone releasing peptide and thyrotropin-releasing hormone in patients with protracted critical illness. Journal of Clinical Endocrinology and Metabolism 1999 84 1311-1323.
7. Thorner MO, Vance ML, Laws ER, Horvath E & Kovacs K. The anterior pituitary. In Williams Textbook of Endocrinology, edn 9, ch 9, pp 249-340. Eds JD Wilson, DW Foster, HM Kronenberg & PR Larsen. Philadelphia: WB Saunders, 1998.
8. Bowers CY, Momany FA, Reynolds GA & Hong A. On the in vitro and in vivo activity of a new synthetic hexapeptide that acts on the pituitary to specifically release growth hormone. Endocrinology 1984 114 1537-1545.
9. Howard AD, Feighner SD, Cully DF, Arena JP, Liberator PA, Rosenblum CI et al. A receptor in pituitary and hypothalamus that functions in growth hormone release. Science 1996 273 974-977.
10. Kojima M, Hosoda H, Date Y & Nakazato M. Ghrelin is a growth-hormone-releasing acylated peptide from stomach. Nature 1999 402 656-660.
11. Gevers EF, Wit JM & Robinson IC. Growth, growth hormone (GH) binding protein, and GH receptors are differentially regulated by peak and trough components of GH secretory pattern in the rat. Endocrinology 1996 137 1013-1018.
12. Giustina A & Veldhuis JD. Pathophysiology of the neuroregulation of growth hormone secretion in experimental animals and the human. Endocrine Reviews 1998 19 717-797.
13. Hindmarsh PC, Dennison E, Pincus SM, Cooper C, Fall CHD, Matthews DR et al. A sexually dimorphic pattern of growth hormone secretion in the elderly. Journal of Clinical Endocrinology and Metabolism 1999 84 2679-2685.
14. Ross R, Miell J, Freeman E, Jones J, Matthews D, Preece M & Buchanan C. Critically ill patients have high basal growth hormone levels with attenuated oscillatory activity associated with low levels of insulin-like growth factor-I. Clinical Endocrinology 1991 35 47-54.
15. Voerman HJ, Strack van Schijndel RJM, de Boer H, van der Veen EA & Thijs LG. Growth hormone: secretion and administration in catabolic adult patients, with emphasis on the critically ill patient. Netherlands Journal of Medicine 1992 41 229-244.
16. Hartman ML, Veldhuis JD, Johnson ML, Lee MM, Alberti KG, Samojlik E et al. Augmented growth hormone secretory burst frequency and amplitude mediate enhanced GH secretion during a two day fast in normal men. Journal of Clinical Endocrinology and Metabolism 1992 74 757-765.
17. Hermansson M, Wickelgren RB, Hammerqvist F, Bjarnason R, Wennstrom I, Wernerman J et al. Measurement of human growth hormone receptor messenger ribonucleic acid by a quantitative polymerase chain reaction-based assay: demonstration of reduced expression after elective surgery. Journal of Clinical Endocrinology and Metabolism 1997 82 421-428.
18. Baxter RC, Hawker FH, To C, Stewart PM & Holman SR. Thirty day monitoring of insulin-like growth factors and their binding proteins in intensive care unit patients. Growth Hormone and IGF Research 1998 8 455-463.
19. Rodriguez-Arnao J, Yarwood Y, Ferguson C, Miell J, Hinds CJ & Ross RJ. Reduction in circulating IGF-I and hepatic IGF-I mRNA levels after caecal ligation and puncture are associated with differential regulation of hepatic IGF-binding protein-1, -2 and -3 mRNA levels. Journal of Endocrinology 1996 151 287-292.
20. Bentham J, Rodriguez-Arnao-J & Ross RJ. Acquired growth hormone resistance in patients with hypercatabolism. Hormone Research 1993 40 87-91.
21. Timmins AC, Cotterill AM, Cwyfan Hughes SC, Holly JM, Ross RJ, Blum W et al. Critical illness is associated with low circulating concentrations of insulin-like growth factors-I and -II, alterations in insulin-like growth factor binding proteins, and induction of an insulin-like growth factor binding protein-3 protease. Critical Care Medicine 1996 24 1460-1466.
22. Gibson FA & Hinds CJ. Growth hormone and insulin-like growth factors in critical illness. Intensive Care Medicine 1997 23 369-378.
23. Van den Berghe G, de Zegher F, Veldhuis JD, Wouters P, Awouters M, Verbruggen W et al. The somatotropic axis in critical illness: effect of continuous GHRH and GHRP-2 infusion. Journal of Clinical Endocrinology and Metabolism 1997 82 590-599.
24. Van den Berghe G, de Zegher F, Baxter RC, Veldhuis JD, Wouters P, Schetz M et al. Neuroendocrinology of prolonged critical illness: effect of continuous thyrotropin-releasing hormone infusion and its combination with growth hormone-secretagogues. Journal of Clinical Endocrinology and Metabolism 1998 83 309-319.
25. Van den Berghe G, de Zegher F, Lauwers P & Veldhuis JD. Growth hormone secretion in critical illness: effect of dopamine. Journal of Clinical Endocrinology and Metabolism 1994 79 1141-1146.
26. Van den Berghe G & de Zegher F. Anterior pituitary function during critical illness and dopamine treatment Critical Care Medicine 1996 24 1580-1590.
27. Micic D, Popovic V, Doknic M, Macut D, Dieguez C & Casanueva FF. Preserved growth hormone (GH) secretion in aged and very old subjects after testing with the combined stimulus GH-releasing hormone plus GH-releasing hexapeptide-6. Journal of Clinical Endocrinology and Metabolism 1998 83 2569-2572.
28. Van den Berghe G, de Zegher F, Bowers CY, Wouters P, Muller P, Soetens F et al. Pituitary responsiveness to growth hormone (GH) releasing hormone, GH-releasing peptide-2 and thyrotropin releasing hormone in critical illness. Clinical Endocrinology 1996 45 341-351.
29. Michalaki M, Vagenakis A, Kalfarentoz F, Makri M & Kyriazopoulou V. Is there any role of IL-6, TNFα and cortisol in the pathogenesis of euthyroid sick syndrome? Proceedings of the 81st Annual Meeting of the Endocrine Society 12-15 June 1999, San Diego, CA, USA. Abstract P3-422.
30. Chopra IJ, Huang TS, Beredo A, Solomon DH, Chua Teco GN & Mead JF. Evidence for an inhibitor of extrathyroidal conversion of thyroxine to 3,5,3′-triiodothyronine in sera of patients with nonthyroidal illness. Journal of Clinical Endocrinology and Metabolism 1985 60 666-672.
31. Romijn JA & Wiersinga WM. Decreased nocturnal surge of thyrotropin in nonthyroidal illness. Journal of Clinical Endocrinology and Metabolism 1990 70 35-42.
32. Bartalena L, Martino E, Brandi LS, Falcone M, Pacchiarotti A, Ricci C et al. Lack of nocturnal serum thyrotropin surge after surgery. Journal of Clinical Endocrinology and Metabolism 1990 70 293-296.
33. Schlienger JL, Sapin R, Capgras T, Gasser F, Monassier JP, Hauer B et al. Evaluation of thyroid function after myocardial infarction. Annales d'Endocrinologie 1991 52 283-288.
34. Rothwell PM & Lawler PG. Prediction of outcome in intensive care patients using endocrine parameters. Critical Care Medicine 1995 23 78-83.
35. van der Poll T, van Zee K, Endert E, Coyle S, Stiles D, Prible J et al. Interleukin-1 receptor blockade does not affect endotoxin-induced changes in plasma thyroid hormone and thyrotropin concentration in man. Journal of Clinical Endocrinology and Metabolism 1995 80 1341-1346.
36. Lim CF, Doctor R, Visser TJ, Krenning EP, Bernard B, van Toor H et al. Inhibition of thyroxine transport into cultured rat hepatocytes by serum of non-uremic critically ill patients: effects of bilirubin and non-esterified fatty acids. Journal of Clinical Endocrinology and Metabolism 1993 76 1165-1172.
37. Gardner DF, Kaplan MM, Stanley CA & Utiger RD. Effect of triiodothyronine replacement on the metabolic and pituitary responses to starvation. New England Journal of Medicine 1979 300 579-584.
38. De Groot LJ. Dangerous dogmas in medicine: the non-thyroidal illness syndrome. Journal of Clinical Endocrinology and Metabolism 1999 84 151-164.
39. Kemperer JD, Klein I, Gomez M, Helm RE, Ojamaa K, Thomas SJ et al. Thyroid hormone treatment after coronary bypass surgery. New England Journal of Medicine 1995 333 1522-1527.
40. Mullis-Jansson SL, Argenziano M, Corwin S, Homma S, Weinberg AD, Williams M et al. A randomized double blind study on the effect of triiodothyronine on cardiac function and morbidity after coronary bypass surgery. Journal of Thoracic and Cardiovascular Surgery 1999 117 1128-1134.
41. Van den Berghe G, de Zegher F, Veldhuis JD, Wouters P, Gouwy S, Stockman W et al. Thyrotropin and prolactin release in prolonged critical illness: dynamics of sponaneous secretion and effects of growth hormone secretagogues. Clinical Endocrinology 1997 47 599-612.
42. Fliers E, Guldenaar SEF, Wiersinga WM & Swaab DF. Thyrotropin-releasing hormone gene expression in the human hypothalamus in relation to non-thyroidal illness. Proceedings of the 79th Annual Meeting of the Endocrine Society, 11-14 June 1997, Minneapolis, MN, USA, Abstract OR44-3.
43. Bacci V, Schussler GC & Kaplan TC. The relationship between serum triiodothyronine and thyrotropin during systemic illness. Journal of Clinical Endocrinology and Metabolism 1982 54 1229-1235.
44. Damas P, Reuter A, Gysen P, Demonty J, Lamy M & Franchimont P. Tumor necrosis factor and interleukin-1 serum levels during severe sepsis in humans. Critical Care Medicine 1989 17 975-978.
45. Faglia G, Ferrari C, Beck-Peccoz P, Spada A, Travaglini P & Ambrosi B. Reduced plasma thyrotropin response to thyrotropin releasing hormone after dexamethasone administration in normal humans. Hormone and Metabolic Research 1973 5 289-291.
46. Van den Berghe G, de Zegher F & Lauwers P. Dopamine and the sick euthyroid syndrome in critical illness. Clinical Endocrinology 1994 41 731-737.
47. Van den Berghe G, Wouters P, Bowers CY, de Zegher F, Bouillon R & Veldhuis JD. Growth hormone releasing peptide-2 infusion synchronizes growth hormone, thyrotropin and prolactin secretion in prolonged critical illness. European Journal of Endocrinology 1999 140 17-22.
48. Arem R, Wiener GJ, Kaplan SG, Kim HS, Reichlin S & Kaplan MM. Reduced tissue thyroid hormone levels in fatal illness. Metabolism 1993 42 1102-1108.
49. Vaughan GM, Mason AD, McManus WF & Pruitt BA Jr. Alterations of mental status and thyroid hormones after thermal injury. Journal of Clinical Endocrinology and Metabolism 1985 60 1221-1225.
50. Brent GA & Hershman JM. Thyroxine therapy in patients with severe non-thyroidal illnesses and low serum thyroxine concentrations. Journal of Clinical Endocrinology and Metabolism 1986 63 1-7.
51. Becker RA, Vaughan GM, Ziegler MG, Seraille LG, Goldfarb IW, Mansour EH et al. Hypermetabolic low triiodothyronine syndrome in burn injury. Critical Care Medicine 1982 10 870-875.
52. Bettendorf M, Schmidt KG, Grenz S, Grulich-Henn J & Heinrich U. Triiodothyronine treatment in children after cardiac surgery: a randomized, placebo-controlled, double-blind clinical study. Proceedings of the 81st Annual Meeting of the Endocrine Society 12-15 June 1999 San Diego, CA, USA. Abstract O12-5.
53. Wang C, Chan V & Yeung RTT. Effect of surgical stress on pituitary-testicular function. Clinical Endocrinology 1978 9 255-266.
54. Wang C, Chan V, Tse TF & Yeung RT. Effect of acute myocardial infarction on pituitary testicular function. Clinical Endocrinology 1978 9 249-253.
55. Dong Q, Hawker F, McWilliam D, Bangah M, Burger H & Handelsman DJ. Circulating immunoreactive inhibin and testosterone levels in patients with critical illness. Clinical Endocrinology 1992 36 399-404.
56. Van den Berghe G, de Zegher F, Lauwers P & Veldhuis JD. Luteinizing hormone secretion and hypoandrogenemia in critically ill men: effect of dopamine. Clinical Endocrinology 1994 41 563-569.
57. Russell DH. New aspects of prolactin and immunity: a lymphocyte-derived prolactin-like product and nuclear protein kinase C activation. Trends in Pharmacological Sciences 1989 10 40-44.
58. Bernton EW, Meltzer MS & Holaday JW. Suppression of macrophage activation and T-lymphocyte function in hypoprolactinemic mice. Science 1988 239 401-404.
59. Russell DH, Larson DF, Cardon SB & Copeland JG. Cyclosporin inhibits prolactin induction of ornithine decarboxylase in rat tissue. Molecular and Cellular Endocrinology 1984 35 159-166.
60. Russell DH, Kibler R, Matrisian L, Larson DF, Poulos B & Magun BE. Prolactin receptors on human T- and B-lymphocytes: antagonism of prolactin-binding by cyclosporin. Journal of Immunology 1985 134 3027-3031.
61. Carrier M, Wild J, Pelletier C & Copeland JG. Bromocriptine as an adjuvant to cyclosporin immunosuppression after heart transplantation. Annals of Thoracic Surgery 1990 49 129-132.
62. Noel GL, Suh HK, Stone SJG & Frantz AE. Human prolactin and growth hormone release during surgery and other conditions of stress. Journal of Clinical Endocrinology and Metabolism 1972 35 840-851.
63. Van den Berghe G, de Zegher F & Lauwers P. Dopamine and the euthyroid sick syndrome in critical illness. Clinical Endocrinology 1994 41 731-737.
64. Meakins JL, Pietsch JB, Bubenick O, Kelly R, Rode H, Gordon J et al. Delayed hypersensitivity: indicator of acquired failure of host defenses in sepsis and trauma. Annals of Surgery 1977 188 241-250.
65. Devins SS, Miller A, Herndon BL, O'Toole L & Reisz G. Effects of dopamine on T-lymphocyte proliferative responses and serum prolactin concentrations in critically ill patients. Critical Care Medicine 1992 263 9682-9685.
66. Belchetz PE, Plant TM, Nakai Y, Keogh EJ & Knobil E. Hypophyseal responses to continuous and intermittent delivery of hypothalamic gonadotropin-releasing hormone. Science 1978 202 631-633.
67. Santoro N, Filicori M & Crowley Jr WF. Hypogonadotropic disorders in men and women: diagnosis and therapy with pulsatile gonadotropin releasing hormone. Endocrine Reviews 1986 7 11-23.
68. Klibanski A, Beitens IZ, Badger TM, Little R & McArthur J. Reproductive function during fasting in man. Journal of Clinical Endocrinology and Metabolism 1981 53 258-266.
69. Veldhuis JD, Iranmanesh A, Evans WS, Lizarralde G, Thorner MO & Vance ML. Amplitude suppression of the pulsatile mode of immunoradiometric LH release in fasting-induced hypoandrogenemia in normal men. Journal of Clinical Endocrinology and Metabolism 1993 76 587-593.
70. Vogel AV, Peake GT & Rada RT. Pituitary-testicular axis dysfunction in burned men. Journal of Clinical Endocrinology and Metabolism 1985 60 658-665.
71. Lephart ED, Baxter CR & Parker CR Jr. Effect of burn trauma on adrenal and testicular steroid hormone production. Journal of Clinical Endocrinology and Metabolism 1987 64 842-848.
72. Kreutz LD, Rose RM & Jennings JR. Suppression of plasma testosterone levels and psychological stress: a longitudinal study of young men in officer candidate school. Archives of General Psychiatry 1972 26 479-482.
73. Aakvaag A, Bentdal O, Quigstad K, Walstad P, Ronningen H & Fonnum F. Testosterone and testosterone binding globulin in young men during prolonged stress. International Journal of Andrology 1978 1 22-31.
74. Rivier C & Vale W. In the rat, interleukin 1-α acts at the level of the brain and the gonads to interfere with gonadotropin and sex steroid secretion. Endocrinology 1989 124 2105-2109.
75. Guo H, Calkins JH, Sigel MM & Lin T. Interleukin-2 is a potent inhibitor of Leydig cell steroidogenesis. Endocrinology 1990 127 1234-1239.
76. Woolf PD, Hamill RW, McDonald JV, Lee LA & Kelly M. Transient hypogonadotropic hypogonadism caused by critical illness. Journal of Clinical Endocrinology and Metabolism 1985 60 444-450.
77. Spratt DI, Cox P, Orav J, Moloney J & Bigos T. Reproductive axis suppression in acute illness is related to disease severity. Journal of Clinical Endocrinology and Metabolism 1993 76 1548-1554.
78. Cicero TJ, Bell RD, Wiest WG, Allison JH, Polakoski K & Robins E. Function of the male sex organs in heroin and methadone users. New England Journal of Medicine 1975 292 882-887.
79. Tweedle D, Walton C & Johnston IDA. The effect of an anabolic steroid on postoperative nitrogen balance. British Journal of Clinical Practice 1972 27 130-132.
80. O'Leary E, Hubbard K, Tormey W & Cunningham AJ. Laparoscopic cholecystectomy: haemodynamic and neuroendocrine responses after pneumoperitoneum and changes in position. British Journal of Anaesthesia 1996 76 640-644.
81. Munck A, Guyre P & Holbrook N. Physiological functions of glucocorticoids during stress and their relation to pharmacological actions. Endocrine Reviews 1984 5 25-44.
82. Starling EH. The Wisdom of The Body. The Harveian Oration delivered to the Royal College of Physicians, London. London: HK Lewis, 1923.
83. Cannon WB. The Wisdom of The Body. New York: Norton, 1932.
84. Vermes I, Bieshuizen A, Hampsink RM & Haanen C. Dissociation of plasma adrenocorticotropin and cortisol levels in critically ill patients: possible role of endothelin and atrial natriuretic hormone. Journal of Clinical Endocrinology and Metabolism 1995 80 1238-1242.
85. Suzuki T, Suzuki N, Daynes RA & Engleman EG. Dehydroepiandrosterone enhances IL2 production and cytotoxic effector function of human T-cells. Clinical Immunology and Immunopathology 1991 61 202-211.
86. Parker LN, Levin ER & Lifrak ET. Evidence for adrenocortical adaptation to severe illness. Journal of Clinical Endocrinology and Metabolism 1985 60 947-952.
87. Van den Berghe G, de Zegher F, Schetz M, Verwaest C, Ferdinande P & Lauwers P. Dehydroepiandrosterone sulphate in critical illness: effect of dopamine. Clinical Endocrinology 1995 43 457-463.
88. Zipser RD, Davenport MW, Martin KL, Tuck ML, Warner NE, Swinney RR et al. Hyperreninemic hypoaldosteronism in the critically ill: a new entity. Journal of Clinical Endocrinology and Metabolism 1981 53 867-873.
89. Barquist E & Kirton O. Adrenal insufficiency in the surgical intensive care unit patient. Journal of Trauma 1997 42 27-31.
90. Yeoh SI & Baxter RC. Metabolic regulation of the growth hormone independent insulin-like growth factor binding protein in human plasma. Acta Endocrinologica 1988 119 465-473.
91. Lewitt MS & Baxter RC. Regulation of growth hormone-independent insulin-like growth factor-binding protein (BP-28) in cultured human fetal liver explants. Journal of Clinical Endocrinology and Metabolism 1989 69 246-252.
92. Lewitt MS & Baxter RC. Inhibitors of glucose uptake stimulate the production of insulin-like growth factor binding protein (IGFBP-1) by human fetal liver. Endocrinology 1990 126 1527-1533.
93. Baxter RC. Circulating binding proteins for the insulin-like growth factors. Trends in Endocrinology and Metabolism 1993 4 91-96.
94. Norrelund H, Fisker S, Vahl N, Borglum J, Richelsen B, Christiansen JS et al. Evidence supporting a direct suppressive effect of growth hormone on serum IGFBP-1 levels: experimental studies in normal, obese and GH-deficient adults. Growth Hormone and IGF Research 1999 9 52-60.
95. Olivecrona H, Hilding A, Ekström C, Barle H, Nyberg B, Möller C et al. Acute and short-term effects of growth hormone on insulin-like growth factors and their binding proteins: serum levels and hepatic messenger ribonucleic acid responses in humans. Journal of Clinical Endocrinology and Metabolism 1999 84 553-560.
96. Delhanty PJD & Baxter RC. The regulation of acid-labile subunit gene expression and secretion by cyclic adenosine 3′,5′-monophosphate. Endocrinology 1998 139 260-265.
97. Hu M, Robertson DG & Murphy LJ. Growth hormone modulates insulin regulation of hepatic insulin-like growth factor binding protein-1 transcription. Endocrinology 1996 137 3702-3709.
98. Takala J, Ruokonen E, Webster NR, Nielsen MS, Zandstra DF, Vundelinckx G et al. Increased mortality associated with growth hormone treatment in critically ill adults. New England Journal of Medicine 1999 341 785-792.